Home

MICHAEL RAAB

CIK 1321402 · President & CEO · last filed 2026-08-25

MICHAEL RAAB is a President & CEO who has filed 150 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider sold $225.9K of ARDX on Aug 25, 2026. Across all open-market trades the lifetime net is −$9.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.89M

Companies

4

Total Filings

150

Lifetime Open-Market Net

-$9.42M

Filer Profile

Reported Address
1119 ST PAUL STREET
BALTIMORE, MD 21202
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARDX President & CEO 1,644,156 $3.58 $5.89M -$8.79M 86 2026-08-25
AMICUS THERAPEUTICS, INC. (FOLD) Delisted Director 0 $14.49 $0 -$629.0K 28 2026-04-27
TPST Director — $0.81 — $0 6 2026-01-28
Paratek Pharmaceuticals, Inc. (NOVC) Delisted Director — — — $0 3 2008-03-31

Recent Filings

150 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-25 ARDX Sell (S) −58,574 -$225.9K EDGAR
2026-08-21 ARDX Notice (144) −44,500 -$179.3K EDGAR
2026-07-17 ARDX Mixed −20,834 -$190.3K EDGAR
2026-06-17 ARDX Notice (144/A) −41,666 -$236.7K EDGAR
2026-06-17 ARDX Mixed −20,833 -$215.7K EDGAR
2026-06-15 ARDX Notice (144) −125,000 -$711.2K EDGAR
2026-05-22 ARDX Sell (S) −54,748 -$343.1K EDGAR
2026-05-19 ARDX Notice (144) −44,500 -$277.2K EDGAR
2026-05-19 ARDX Mixed −20,833 -$241.0K EDGAR
2026-04-27 AMICUS THERAPEUTICS, INC. (FOLD) Delisted Disp (D) −115,857 -$1.68M EDGAR
Showing 1–10 of 150
Page 1 of 15
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.